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Purpose: Lamins are the major component of nuclear lamina,
maintaining structural integrity of the nucleus. Lamin A/C variants
are well established to cause a spectrum of disorders ranging from
myopathies to progeria, termed laminopathies. Phenotypes result-
ing from variants in LMNB1 and LMNB2 have been much less
clearly defined.
Methods: We investigated exome and genome sequencing from
the Deciphering Developmental Disorders Study and the 100,000
Genomes Project to identify novel microcephaly genes.
Results: Starting from a cohort of patients with extreme micro-
cephaly, 13 individuals with heterozygous variants in the two human
B-type lamins were identified. Recurrent variants were established to
be de novo in nine cases and shown to affect highly conserved residues
within the lamin ɑ-helical rod domain, likely disrupting interactions
required for higher-order assembly of lamin filaments.
Conclusion: We identify dominant pathogenic variants in LMNB1
and LMNB2 as a genetic cause of primary microcephaly,
implicating a major structural component of the nuclear envelope
in its etiology and defining a new form of laminopathy. The distinct
nature of this lamin B–associated phenotype highlights the
strikingly different developmental requirements for lamin paralogs
and suggests a novel mechanism for primary microcephaly
warranting future investigation.
Genetics in Medicine (2021) 23:408–414; https://doi.org/10.1038/s41436-
020-00980-3
Key words: LMNB1; LMNB2; laminopathy; primary microce-
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INTRODUCTION
The nuclear lamina is a protein structure that lines the inner
nuclear membrane and provides structural support to the
nucleus.1 Lamins are the major component of the nuclear
lamina, forming a meshwork of filaments; they interact with
numerous proteins and also act as a signaling hub, linking the
nuclear lamina to the cytoskeleton and chromatin. Conse-
quently, as well as maintaining structural integrity of the
nucleus, they influence chromatin organization, DNA tran-
scription, repair, and replication.1
Vertebrate cells express two classes of lamins, A and B,
grouped based on sequence homology. Lamins A and C (A-
types) are splice isoforms encoded by the same gene, while the
B-type lamins are the products of different genes.1
Over the past two decades many disorders have been linked
to LMNA variants, collectively termed laminopathies. Four
major disease categories have been described with overlapping
features: striated muscle diseases, lipodystrophy syndromes,
peripheral neuropathies, and accelerated aging (segmental
progeroid) disorders.2
In contrast to LMNA, few reports have associated
human disease with variants in B-type lamin genes. No
pathogenic single-nucleotide variants in LMNB1 have been
reported, although genomic duplications incorporating
LMNB1 cause adult-onset leukodystrophy (MIM 169500).3
For LMNB2, a homozygous missense variant in a family
with progressive myoclonic epilepsy and ataxia has been
described.4 Enrichment of heterozygous LMNB2 variants in
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acquired partial lipodystrophy patients has also been
reported.5
Microcephaly is a reduction in head size, defined by a head
circumference at least three standard deviations below the
mean for age and gender. The underlying reduction in brain
volume has many etiologies: chromosomal, environmental, as
well as single-gene syndromic and nonsyndromic causes.
Primary microcephaly represents a recognizable monogenic
form of microcephaly in which brain size is markedly reduced
in the absence of other malformations and/or significant
neurological deficits aside from intellectual disability.6 Many
genes associated with centrosome and/or mitotic spindle
function have been described, suggesting primary micro-
cephaly to be a disorder of neural stem cell mitosis.7
Here we report the identification of recurrent heterozygous
variants in LMNB1 and LMNB2, implicating the nuclear
lamina in the etiology of microcephaly.
MATERIALS AND METHODS
Ethics statement
Ethical approval was obtained as follows: Scottish Multicentre
Research Ethics Committee (05/MRE00/74); Deciphering
Developmental Disorders (DDD) Study (10/H0305/83, Cam-
bridge South REC; GEN/284/12 Republic of Ireland REC);
100,000 Genomes Project (100kGP), East of
England–Cambridge South REC (14/EE/1112). Informed
written consent obtained for all participating families. Parents
provided written authorization for publication of clinical
photographs.
Bioinformatics
DDD Study exome sequencing and variant calling were
performed as previously described.8 De novo variants were
identified using VASE (v0.2.4, https://github.com/david-a-
parry/vase). For 100kGP, variants and Human Phenotype
Ontology (HPO) terms were extracted from the Genomics
England research environment.
For de novo variant calling criteria, structural modeling,
and immunofluorescence experiment methodology, see Sup-
plementary methods.
RESULTS
Identification of LMNB1 pathogenic variants
To identify novel microcephaly genes, DDD exome sequen-
cing data were analyzed in a subset of 1056 trios and
singletons where the proband had microcephaly (occipital
frontal circumference [OFC] <−4 SD below age and sex-
matched mean; ~43% cases primary, 57% secondary micro-
cephaly). This identified two individuals (P1 and P2) with de
novo variants in LMNB1 (Table S1, S2) resulting in
substitution or deletion of the same amino acid residue
(NM_005573.4:c.97A>G, p.Lys33Glu and c.97_99del,
p.Lys33del). P3 was also heterozygous for the same
c.97_99del variant but not confirmed de novo as the family
was lost to follow up. In the 100kGP cohort further variants in
LMNB1 were identified in microcephalic patients, with P9
and P11 also having the same de novo c.97A>G variant as P1
(Table S3). An additional recurrent substitution (c.269G>C,
p.Arg90Pro) was identified in P10 and P13. This was
confirmed to be de novo in P10; however, no parental data
were available for P13.
In total, three recurrent LMNB1 variants were identified in
seven individuals (Fig. 1a), none of which were reported in
gnomAD (v2.1). All were at residues conserved in all lamin
metazoan homologs (Fig. 1b) and predicted damaging by
multiple in silico tools (Table S4).
LMNB2 variants associated with microcephaly
Following identification of variants in LMNB1, we assessed
whether variants in its close homolog LMNB2 were also
associated with microcephaly. We identified four microce-
phalic individuals from the DDD cohort (P4, P5, P6, P7) and
one individual from the 100kGP study (P12) with the same
variant in LMNB2 (NM_032737.4: c.1192G>A, p.Glu398Lys)
(Tables S1–S3). For cases P4, P5, and P12, the variant was
established to be de novo, while in P7, it had been inherited
from the proband’s mosaic, clinically unaffected, mother
(Fig. S1). Finally, another case was identified with a distinct
missense de novo variant (c.160A>C, p.Asn54His).
These variants were absent from gnomAD (v2.1), at highly
conserved residues (Fig. 1b) and predicted damaging
(Table S4).
In total, in 13 microcephalic individuals we identified
5 separate variants absent from the general population, 9 of
which were established to be de novo events, and 4 of which
had occurred recurrently. Taken together, this provided
strong genetic evidence for heterozygous variants in LMNB1
and LNMB2 as a cause of microcephaly.
Clinical phenotype of LMNB1/2 individuals
All LMNB1/2 cases had severe microcephaly (OFC −5.85 ±
1.14 SD, Fig. 2a, Table S5), evident from birth in all but one
case. No intrauterine growth retardation was evident, with
birth weights within normal range. Postnatally, height also
remained within normal ranges for most cases. Global
developmental delay of varying severity was evident and
seizures present in four cases (Tables S1, S3). Major
malformations were not reported. Neuroimaging demon-
strated a structurally normal brain, without evidence of
abnormal neuronal migration (Fig. 2b). In two cases gyral
simplification was noted accompanied by global reduction in
white matter volume alongside increased extra-axial spaces
and enlarged ventricles. In P8, where serial scans were
available, this was nonprogressive. Facially, aside from a
sloping forehead in some individuals, a syndromic diagnosis
was not evident, nor was a consistent facial gestalt observed
(Fig. 2c).
Predicted consequences for lamin B1/B2 polymer assembly
While no LMNB1/2 protein structures are available that cover
regions where the variants occur, all mutated residues are
conserved with LMNA. Therefore, LMNA crystal structures
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could be used to model the substitutions. Each variant alters a
residue in a coiled-coil segment of the α-helical rod domain of
LMNB1/2 (Fig. 1a). LMNB1 Lys33 and LMNB2 Asn54 lie at
the intradimer interface of coil 1A, LMNB1 Arg90 is at the
interdimer interface of coil 1B, and LMNB2 Glu398 is at
the intradimer interface of coil 2B. Substitution or deletion
of these residues would therefore likely interfere with dimer
or filament assembly. Notably, both p.Lys33Glu and
1B1A 2A 2B IG-like
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p.Glu398Lys result in mutated residues with opposite
electrostatic charges to the wild-type residue. LMNA
Glu383, corresponding to LMNB2 Glu398, is established to
separate the two lamin chains of the dimer at the end of the
rod domain, where it repels Glu383 from the other chain.9
Therefore the heterozygous LMNB2 p.Glu398Lys substitution
would result in a subset of mismatched dimers in which,
instead, interaction of the two chains would be aberrantly
stabilized, with a positively charged mutant lysine residue
forming ionic interactions with the negatively charged wild-
type glutamate. Molecular modeling with FoldX predicts this
substitution to strongly stabilize the interdimer interaction
(ΔΔG of −2.0 kcal/mol, Table S6), in keeping with a proposed
stabilizing mechanism for pathogenic LMNA variants.10
Evidence for pathogenicity can also be drawn from the
observation that all mutated codons are conserved in lamin A/
C paralogs. Indeed, three of the LMNB variants (Lys33,
Asn54, Arg90) correspond to residues in LMNA that are
altered in lamin A/C associated disorders.11 As substitution of
these sites in LMNA are disease causing, this would also be
expected to be the case in LMNB1/B2. Furthermore, LMNB1
p.Lys33del has already been modeled in the ancestral C.
elegans LMN (a protein most homologous to B-type lamins1)
where it disrupts protofilament assembly in vitro and causes
nuclear aggregates of lamin in vivo.12
Lastly, we examined the cellular distribution of GFP-lamin
B fusion proteins containing microcephaly variants, in a
similar manner to that done previously for LMNA variants.13
Cells expressing the LMNB1/B2 variants frequently contained
nuclear aggregates and/or significantly altered nuclear mor-
phology in comparison to cells expressing wild-type GFP-
LMNB1/2 (Fig. S2, Tables S8 and S9). While GFP-LMNB1/2
proteins were expressed above endogenous levels, both
aggregates and altered nuclear shape have previously been
reported for pathogenic lamin A/C variants, both when
overexpressed13 and at endogenous levels,12,14 leading us to
conclude that lamin B variants may also disrupt lamin
assembly in cells.
DISCUSSION
LMNB primary microcephaly: a new laminopathy
Here we identify recurrent and de novo heterozygous variants
in LMNB1 and LMNB2 in eight microcephaly patients from
the DDD cohort. The additional five cases ascertained from
100kGP on the basis of de novo or recurrent variants in
LMNB1/2 also had microcephaly, confirming the
phenotype–genotype link. A severe nonsyndromic microce-
phaly without other malformations was consistently present.
In keeping with primary microcephaly, all but one case had a
reduced OFC evident at birth, and neuroimaging demon-
strated a structurally normal small brain with/without a
simplified gyral pattern. Dilated ventricles and increased axial
spaces have been previously documented,15,16 as have seizures
in a minority of primary microcephaly cases. Primary
microcephaly is usually accompanied by mild/moderate
intellectual disability, although for LMNB1/2 global develop-
mental delay varied substantially between cases, classified as
severe in four of eight DDD cases, with speech not attained in
three older children.
The LMNB1/B2 microcephaly phenotype is distinct from
previously described lamin A/C laminopathies, pointing to
different cellular and developmental roles for lamin B
proteins, despite all lamins acting as major structural
components of the nuclear envelope. The human micro-
cephaly is in keeping with the previously reported mouse
knockout model for Lmnb1 in which cerebral cortical size was
markedly reduced.17 However, in both the Lmnb1−/− and
Lmnb2−/− mice, (where brain size was not reduced at birth),
there were neuronal migration defects resulting in abnormal
layering of the cerebral cortex,18 suggesting potential
discordance with the human phenotype and neuroimaging
findings. This may be accounted for however by a different
mechanism in human cases where variants are heterozygous
rather than biallelic null. The pathogenic variants reported
here are most likely dominant negative rather than haploin-
sufficient given that microcephaly is not present in the
Lmnb1+/− mouse. The recurrent nature of the pathogenic
variants at specific residues and absence of truncating variants
favors gain of function or dominant negative mechanisms.
Furthermore, substitutions in corresponding residues in lamin
A/C do not destabilize the protein, rather disrupt lamin
filament formation,19 a common scenario by which point
variants in multimeric proteins can act in a dominant negative
manner to perturb macromolecular complexes.20
LMNB1 and LMNB2 have overlapping but distinctive
cellular and developmental roles.1 So it is striking that
Fig. 1 Pathogenic LMNB1 and LMNB2 variants occur recurrently at highly conserved residues at intra- and interdimer filament
interfaces. (a) Schematic of B-type lamin protein structure. Locations of variants identified in microcephaly patients indicated, number of occurrences in
parentheses. The ɑ-helical rod comprises coiled-coil domains 1A, 1B and 2A, 2C, indicated by green and purple boxes respectively. IG-like, immunoglobulin-
like domain; NLS, nuclear localization signal. (b) Variants alter residues conserved in all vertebrate and invertebrate lamins. Lamins are specific to metazoa
and the number of lamin genes has increased during evolution, with a single lamin gene in C. elegans compared with three mammalian lamin genes.
Orthologs of both A- and B-type lamins aligned using Clustal X and colored by percent identity using Jalview. (c) Location of altered residues within lamin
structures. While LMNB1/2 structures covering the mutated residues have not been published, as all residues are conserved with LMNA, we could use crystal
structures of LMNA with Protein Data Bank (PDB) accessions 6JLB (i) and 1X8Y (ii) for molecular modeling and visualization. The upper structures shows a
LMNA homotetramer, with the mutated residues highlighted on one of the constituent homodimers, while the bottom structure is of a LMNA homodimer,
as no higher-order structure is available for this region. (d) Lamin filaments are assembled in a hierarchical fashion. First, lamin proteins form dimers, which
further assemble into head to tail polymers. These polymers then laterally assemble in an antiparallel fashion to form lamin protofilaments.
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pathogenic variants in both cause primary microcephaly,
suggesting an etiology in which a shared function is
disrupted. Many primary microcephaly proteins are
involved in mitosis, and often encode centrosomal or
spindle components that when mutated result in altered
spindle orientations disrupting symmetric cell division
dynamics in neural progenitors.7 This reduces neuronal
cell number generated during neurogenesis. B-type lamins
associate with the mitotic spindle21 with defects in spindle
orientation in neuronal precursor cells reported in Lmnb1
and Lmnb2 knockout mice,17 suggesting this could be the
mechanism underlying microcephaly. Other mitotic pro-
cesses may also be perturbed, given the involvement of
LMNs in nuclear envelope reassembly. However, the
potential for LMNB1/2 variants to alter the physical
properties of lamin dimers and filaments (Fig. 1c) should
also be considered, given that several of the variants are seen
to impact on cellular assembly of nuclear lamina, and that
the equivalent pathogenic LMNA variant to LMNB1
p.Lys33del results in fragile nuclei more prone to mechan-
ical deformation.22 Such fragility in neuronal precursors




































Fig. 2 Pathogenic LMNB1 or LMNB2 variants in patients with primary microcephaly. (a) Growth parameters of individuals with pathogenic LMNB1/
2 variants plotted as Z-scores (standard deviations from the age and sex-matched mean). Black bars, mean Z-score. Dashed lines, 95% confidence interval
for general population. (b) Neuroimaging demonstrates reduced cortical size with simplified gyri. Ventricular dilatation reflects accompanying global
reduction in white matter. Comparison with age-matched control. Scale bar 2 cm. Axial images, T2-weighted. Coronal, T2 (P8), fluid-attenuated inversion
recovery (FLAIR) (control). (c) Photographs of individuals P4, P5, P6, and P8. Written consent obtained from families for photography. OFC occipital frontal
circumference.
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interkinetic nuclear migration and neuronal migration and
lead to increased cell death during brain development.23
Notably, several genes encoding components of the nuclear
pore have also been implicated in microcephaly. While
nuclear pores are also important components of the nuclear
envelope, these are generally clinically distinct disorders, often
associated with nephrotic syndrome (Galloway–Mowat
syndrome24,25) or with a progressive microcephaly/
encephalopathy.26,27 As well, nuclear–cytoplasmic transport
has been demonstrated to be impaired,27 so the microcephaly
in nuclear pore disorders could have a different
mechanistic basis.
In conclusion, our findings establish heterozygous
variants in LMNB1 and LMNB2 as causes of primary
microcephaly, implicating the nuclear lamina in its etiology
and defining a novel form of laminopathy. Future in vitro and
in vivo studies will be important to provide further evidence
for causality of the variants reported here, and to shed light on
how they cause a laminopathy distinct from those previously
described.
SUPPLEMENTARY INFORMATION
The online version of this article (https://doi.org/10.1038/s41436-
020-00980-3) contains supplementary material, which is available
to authorized users.
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